Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease

• Main Authors: Vipul Yadav (Author), Aileen House (Author), Silvia Matiz (Author), Laura E. McCoubrey (Author), Kimberly A. Bettano (Author), Leena Bhave (Author), Meiyao Wang (Author), Peter Fan (Author), Siqun Zhou (Author), Janice D. Woodhouse (Author), Eirini Poimenidou (Author), Liu Dou (Author), Abdul W. Basit (Author), Lily Y. Moy (Author), Robert Saklatvala (Author), Laxminarayan G. Hegde (Author), Hongshi Yu (Author)
• Format: Book
• Published: MDPI AG, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/pharmaceutics14112385; 1999-4923
• Keywords: JAK inhibitors; colonic drug delivery; drug stability; ulcerative colitis; Crohn's disease; anti-inflammatory; Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 14, Iss 11, p 2385 (2022)

Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and filgotinib (Jyseleca), have been approved for treatment of ulcerative colitis with several other JAK inhibitors in late-stage clinical trials for inflammatory bowel disease (IBD). Despite their impressive efficacy, the risk of adverse effects accompanying the use of JAK inhibitors has brought the entire class under scrutiny, leading to them receiving an FDA black box warning. In this study we investigated whether ileocolonic-targeted delivery of a pan-JAK inhibitor, tofacitinib, can lead to increased tissue exposure and reduced systemic exposure compared to untargeted formulations. The stability of tofacitinib in the presence of rat colonic microbiota was first confirmed. Next, in vivo computed tomography imaging was performed in rats to determine the transit time and disintegration site of ileocolonic-targeted capsules compared to gastric release capsules. Pharmacokinetic studies demonstrated that systemic drug exposure was significantly decreased, and colonic tissue exposure increased at 10 mg/kg tofacitinib dosed in ileocolonic-targeted capsules compared to gastric release capsules and an oral solution. Finally, in a rat model of LPS-induced colonic inflammation, targeted tofacitinib capsules significantly reduced concentrations of proinflammatory interleukin 6 in colonic tissue compared to a vehicle-treated control (<i>p</i> = 0.0408), unlike gastric release tofacitinib capsules and orally administered dexamethasone. Overall, these results support further development of ileocolonic-targeted tofacitinib, and potentially other specific JAK inhibitors in pre-clinical and clinical development, for the treatment of IBD.